Usefulness and limitations of rituximab in managing patients with lymphoproliferative disorder after heart transplantation.
Exp Clin Transplant
; 10(5): 513-8, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-22747415
ABSTRACT
Posttransplant lymphoproliferative disorders remain an uncommon complication of heart transplant with a high mortality rate reported after conventional therapies. Four patients with posttransplant lymphoproliferative disorders, of whom 3 were CD20 positive, received intravenous dosages of rituximab, 375 mg/m(2), weekly, for 6 ± 2 weeks. The overall response rate was 75% with 3 complete responses (CD20 positive) and 1 case of progressive disease (CD20 negative). Rituximab should be considered as a first-line therapy for patients with CD20 positive posttransplant lymphoproliferative disorders.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Complicaciones Posoperatorias
/
Trasplante de Corazón
/
Anticuerpos Monoclonales de Origen Murino
/
Factores Inmunológicos
/
Trastornos Linfoproliferativos
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2012
Tipo del documento:
Article